Dendritic cells immunotherapy based

Morisaki, T., K. Matsumoto, H. Onishi, H. Kuroki, E. Baba, A. Tasaki, M. Kubo, M. Nakamura, S. Inaba, K. Yamaguchi, M. Tanaka, and M. Katano (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients rationale, current progress, and perspectives. Hum Cell 16 175-182. 

Adoptive dendritic cell-based immunotherapy represents a promising approach to overcoming peripheral tolerance against autologous tumor antigens and to maintaining protective antitumor immunity. The translation of successful preclinical studies, however, appears to be hampered by new complexities associated with the clinical situation. 

Akiyama Y, Maruyama K, Nara N, Hojo T, Cheng JY, Mori T, Wiltrout RH, Yamaguchi K. Antitumor effects induced by dendritic cell-based immunotherapy against established pancreatic cancer in hamsters. Cancer Lett 2002 184 37—47. 

De Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, Goffin J et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res 2008 14 3098-3104. 

Kirk, C. J., Hartigan-O Connor, D., Nickoloff, B. J., Chamberlain, J. S., Giedhn, M., Aukerman, L., et al. (2001). T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine Augmentation of dendritic cell-based immunotherapy. 

Buchler, T., J. Michalek, L. Kovarova, R. Musilova, and R. Hajek. 2003. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Hematology 8(2) 97-104. 

---